Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT03523585




Registration number
NCT03523585
Ethics application status
Date submitted
13/04/2018
Date registered
14/05/2018
Date last updated
5/11/2024

Titles & IDs
Public title
DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]
Scientific title
A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study of Trastuzumab Deruxtecan (DS-8201a), an Anti-HER2-antibody Drug Conjugate, Versus Treatment of Investigator's Choice for HER2-positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1
Secondary ID [1] 0 0
2018-000221-31
Secondary ID [2] 0 0
DS8201-A-U301
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Breast Cancer 0 0
Condition category
Condition code
Cancer 0 0 0 0
Breast

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Trastuzumab deruxtecan
Treatment: Drugs - Capecitabine
Treatment: Drugs - Lapatinib
Treatment: Drugs - Trastuzumab

Experimental: Trastuzumab deruxtecan (DS-8201a) - HER2 positive, unresectable and/or metastatic breast cancer participants previously treated with standard of care HER2 therapies, including ado-trastuzumab emtansine (T-DM1), randomized to treatment with DS-8201a

Active comparator: Trastuzumab+capecitabine - HER2 positive, unresectable and/or metastatic breast cancer participants previously treated with standard of care HER2 therapies, including ado-trastuzumab emtansine (T-DM1), randomized to investigator's choice treatment with Trastuzumab/capecitabine

Active comparator: Lapatinib+capecitabine - HER2 positive, unresectable and/or metastatic breast cancer participants previously treated with standard of care HER2 therapies, including ado-trastuzumab emtansine (T-DM1), randomized to investigator's choice treatment with Lapatinib/capecitabine


Treatment: Drugs: Trastuzumab deruxtecan
DS-8201a is sterile lyophilized powder reconstituted into a sterile aqueous solution (100 mg/5 mL) to be administered as intravenous (IV) dose

Treatment: Drugs: Capecitabine
Investigator's choice Standard of Care when combined with trastuzumab or lapatinib

Treatment: Drugs: Lapatinib
Investigator's choice Standard of Care when combined with capecitabine

Treatment: Drugs: Trastuzumab
Investigator's choice Standard of Care when combined with capecitabine
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Progression-Free Survival (PFS) Based on Blinded Independent Central Review (BICR) in Participants With HER2-positive, Unresectable and/or Metastatic Breast Cancer Participants Previously Treated With Trastuzumab Emtansine
Timepoint [1] 0 0
Baseline up to 46 months postdose
Secondary outcome [1] 0 0
Overall Survival (OS) in Participants With HER2-positive, Unresectable and/or Metastatic Breast Cancer Participants Previously Treated With Trastuzumab Emtansine
Timepoint [1] 0 0
Baseline up to 46 months postdose
Secondary outcome [2] 0 0
Percentage of Participants With Objective Response Rate (ORR) in Participants With HER2-positive, Unresectable and/or Metastatic Breast Cancer Participants Previously Treated With Trastuzumab Emtansine
Timepoint [2] 0 0
Baseline up to 46 months postdose
Secondary outcome [3] 0 0
Duration of Response (DoR) Based on BICR in Participants With HER2-positive, Unresectable and/or Metastatic Breast Cancer Participants Previously Treated With Trastuzumab Emtansine
Timepoint [3] 0 0
Baseline up to 46 months postdose
Secondary outcome [4] 0 0
Progression-Free Survival (PFS) Based on Investigator Assessment in Participants With HER2-positive, Unresectable and/or Metastatic Breast Cancer Participants Previously Treated With Trastuzumab Emtansine
Timepoint [4] 0 0
Up to 46 months

Eligibility
Key inclusion criteria
* Is the age of majority in their country
* Has pathologically documented breast cancer that:

1. is unresectable or metastatic
2. has confirmed HER2-positive expression as determined according to American Society of Clinical Oncology - College of American Pathologists guidelines evaluated at a central laboratory
3. was previously treated with ado-trastuzumab emtansine (T-DM1)
* Has documented radiologic progression (during or after most recent treatment or within 6 months after completing adjuvant therapy)
* Is HER2 positive as confirmed by central laboratory assessment of most recent tumor tissue sample available. If archived tissue is not available, agrees to provide a fresh biopsy.
* Male and female participants of reproductive/childbearing potential must agree to use a highly effective form of contraception or avoid intercourse during and upon completion of the study and for at least:

1. 7 months after the last dose of DS-8201a (females); 4.5 months after last dose of DS-8201a (males)
2. 6 months after the last dose of lapatinib/capecitabine for female participants (3 months for male participants)
3. 7 months after the last dose of trastuzumab/capecitabine
* Has adequate hematopoietic, renal and hepatic functions
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Has previously participated in an antibody drug conjugate study sponsored by Daiichi Sankyo. Prior treatment in the adjuvant/neo-adjuvant setting would be allowed if progression of disease did not occur within 12 months of end of adjuvant therapy
* Has had prior treatment with capecitabine
* Has uncontrolled or significant cardiovascular disease
* Has a history of (noninfectious) interstitial lung disease (ILD)/pneumonitis that required steroids, has current ILD/pneumonitis, or suspected ILD/pneumonitis that cannot be ruled out by imaging at screening
* Has active central nervous system (CNS) metastases

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/08/2018
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
31/07/2025
Actual
Sample size
Target
Accrual to date
Final
608
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC,WA
Recruitment hospital [1] 0 0
St Vincent's Hospital Sydney - Darlinghurst
Recruitment hospital [2] 0 0
Liverpool Hospital - Liverpool
Recruitment hospital [3] 0 0
Macquarie University Hospital - Sydney
Recruitment hospital [4] 0 0
The Tweed Hospital - Tweed Heads
Recruitment hospital [5] 0 0
Princess Alexandra Hospital - Woolloongabba
Recruitment hospital [6] 0 0
Ashford Cancer Centre Research - Kurralta Park
Recruitment hospital [7] 0 0
Box Hill Hospital - Box Hill
Recruitment hospital [8] 0 0
Frankston Hospital - Frankston
Recruitment hospital [9] 0 0
Peninsula and South Eastern Haematology & Oncology Group - Frankston
Recruitment hospital [10] 0 0
Austin Health - Heidelberg
Recruitment hospital [11] 0 0
Peter MacCallum Cancer Centre - Melbourne
Recruitment hospital [12] 0 0
Sunshine Hospital - Saint Albans
Recruitment hospital [13] 0 0
South West Oncology - Warrnambool
Recruitment hospital [14] 0 0
Ballarat Oncology & Haematology Service - Wendouree
Recruitment hospital [15] 0 0
St John of God Subiaco Hospital - Subiaco
Recruitment hospital [16] 0 0
Calvary North Adelaide Hospital - Bruce
Recruitment postcode(s) [1] 0 0
2010 - Darlinghurst
Recruitment postcode(s) [2] 0 0
2170 - Liverpool
Recruitment postcode(s) [3] 0 0
2109 - Sydney
Recruitment postcode(s) [4] 0 0
2485 - Tweed Heads
Recruitment postcode(s) [5] 0 0
4102 - Woolloongabba
Recruitment postcode(s) [6] 0 0
5037 - Kurralta Park
Recruitment postcode(s) [7] 0 0
3128 - Box Hill
Recruitment postcode(s) [8] 0 0
3199 - Frankston
Recruitment postcode(s) [9] 0 0
3084 - Heidelberg
Recruitment postcode(s) [10] 0 0
3000 - Melbourne
Recruitment postcode(s) [11] 0 0
3021 - Saint Albans
Recruitment postcode(s) [12] 0 0
3280 - Warrnambool
Recruitment postcode(s) [13] 0 0
3355 - Wendouree
Recruitment postcode(s) [14] 0 0
6008 - Subiaco
Recruitment postcode(s) [15] 0 0
2614 - Bruce
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Connecticut
Country [4] 0 0
United States of America
State/province [4] 0 0
District of Columbia
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Georgia
Country [7] 0 0
United States of America
State/province [7] 0 0
Hawaii
Country [8] 0 0
United States of America
State/province [8] 0 0
Illinois
Country [9] 0 0
United States of America
State/province [9] 0 0
Indiana
Country [10] 0 0
United States of America
State/province [10] 0 0
Kentucky
Country [11] 0 0
United States of America
State/province [11] 0 0
Maine
Country [12] 0 0
United States of America
State/province [12] 0 0
Maryland
Country [13] 0 0
United States of America
State/province [13] 0 0
Massachusetts
Country [14] 0 0
United States of America
State/province [14] 0 0
Michigan
Country [15] 0 0
United States of America
State/province [15] 0 0
Missouri
Country [16] 0 0
United States of America
State/province [16] 0 0
New York
Country [17] 0 0
United States of America
State/province [17] 0 0
Ohio
Country [18] 0 0
United States of America
State/province [18] 0 0
Pennsylvania
Country [19] 0 0
United States of America
State/province [19] 0 0
Tennessee
Country [20] 0 0
United States of America
State/province [20] 0 0
Texas
Country [21] 0 0
United States of America
State/province [21] 0 0
Utah
Country [22] 0 0
United States of America
State/province [22] 0 0
Virginia
Country [23] 0 0
United States of America
State/province [23] 0 0
Washington
Country [24] 0 0
Belgium
State/province [24] 0 0
Bruxelles
Country [25] 0 0
Belgium
State/province [25] 0 0
Gent
Country [26] 0 0
Belgium
State/province [26] 0 0
Kortrijk
Country [27] 0 0
Belgium
State/province [27] 0 0
Leuven
Country [28] 0 0
Belgium
State/province [28] 0 0
Namur
Country [29] 0 0
Brazil
State/province [29] 0 0
Bahia
Country [30] 0 0
Brazil
State/province [30] 0 0
Ceará
Country [31] 0 0
Brazil
State/province [31] 0 0
Minas Gerais
Country [32] 0 0
Brazil
State/province [32] 0 0
Rio Grande Do Sul
Country [33] 0 0
Brazil
State/province [33] 0 0
Santa Catarina
Country [34] 0 0
Brazil
State/province [34] 0 0
Sao Paulo
Country [35] 0 0
Brazil
State/province [35] 0 0
Rio De Janeiro
Country [36] 0 0
Brazil
State/province [36] 0 0
São Paulo
Country [37] 0 0
Czechia
State/province [37] 0 0
Brno
Country [38] 0 0
Czechia
State/province [38] 0 0
Olomouc
Country [39] 0 0
Czechia
State/province [39] 0 0
Prague 5
Country [40] 0 0
Czechia
State/province [40] 0 0
Praha
Country [41] 0 0
France
State/province [41] 0 0
Bouches-du-Rhône
Country [42] 0 0
France
State/province [42] 0 0
Calvados
Country [43] 0 0
France
State/province [43] 0 0
Cotes d'Armor
Country [44] 0 0
France
State/province [44] 0 0
Côte-d'Or
Country [45] 0 0
France
State/province [45] 0 0
Doubs
Country [46] 0 0
France
State/province [46] 0 0
Finistere
Country [47] 0 0
France
State/province [47] 0 0
Hauts De Seine
Country [48] 0 0
France
State/province [48] 0 0
Herault
Country [49] 0 0
France
State/province [49] 0 0
Ille Et Vilaine
Country [50] 0 0
France
State/province [50] 0 0
Nord
Country [51] 0 0
France
State/province [51] 0 0
Paris
Country [52] 0 0
France
State/province [52] 0 0
Pyrenees Atlantiques
Country [53] 0 0
France
State/province [53] 0 0
Rhone
Country [54] 0 0
France
State/province [54] 0 0
Sarthe
Country [55] 0 0
France
State/province [55] 0 0
Seine Maritime
Country [56] 0 0
France
State/province [56] 0 0
Vaculuse
Country [57] 0 0
France
State/province [57] 0 0
Val De Marne
Country [58] 0 0
France
State/province [58] 0 0
Montpellier
Country [59] 0 0
Germany
State/province [59] 0 0
Bayern
Country [60] 0 0
Germany
State/province [60] 0 0
Rheinland Pfalz
Country [61] 0 0
Germany
State/province [61] 0 0
Schleswig Holstein
Country [62] 0 0
Germany
State/province [62] 0 0
Berlin
Country [63] 0 0
Germany
State/province [63] 0 0
Düsseldorf
Country [64] 0 0
Germany
State/province [64] 0 0
Erlangen
Country [65] 0 0
Germany
State/province [65] 0 0
Koeln
Country [66] 0 0
Germany
State/province [66] 0 0
Leipzig
Country [67] 0 0
Germany
State/province [67] 0 0
Munich
Country [68] 0 0
Germany
State/province [68] 0 0
Müenster
Country [69] 0 0
Germany
State/province [69] 0 0
Troisdorf
Country [70] 0 0
Greece
State/province [70] 0 0
Athens
Country [71] 0 0
Greece
State/province [71] 0 0
Heraklion
Country [72] 0 0
Greece
State/province [72] 0 0
Thessaloníki
Country [73] 0 0
Israel
State/province [73] 0 0
Haifa
Country [74] 0 0
Israel
State/province [74] 0 0
Jerusalem
Country [75] 0 0
Israel
State/province [75] 0 0
Kfar Saba
Country [76] 0 0
Israel
State/province [76] 0 0
Petah tikva
Country [77] 0 0
Israel
State/province [77] 0 0
Ramat Gan
Country [78] 0 0
Israel
State/province [78] 0 0
Tel Aviv
Country [79] 0 0
Italy
State/province [79] 0 0
Milano
Country [80] 0 0
Italy
State/province [80] 0 0
Pordenone
Country [81] 0 0
Italy
State/province [81] 0 0
Verona
Country [82] 0 0
Italy
State/province [82] 0 0
Bergamo
Country [83] 0 0
Italy
State/province [83] 0 0
Bologna
Country [84] 0 0
Italy
State/province [84] 0 0
Cona
Country [85] 0 0
Italy
State/province [85] 0 0
Genova
Country [86] 0 0
Italy
State/province [86] 0 0
Lecco
Country [87] 0 0
Italy
State/province [87] 0 0
Messina
Country [88] 0 0
Italy
State/province [88] 0 0
Modena
Country [89] 0 0
Italy
State/province [89] 0 0
Napoli
Country [90] 0 0
Italy
State/province [90] 0 0
Padova
Country [91] 0 0
Italy
State/province [91] 0 0
Parma
Country [92] 0 0
Italy
State/province [92] 0 0
Pavia
Country [93] 0 0
Italy
State/province [93] 0 0
Pisa
Country [94] 0 0
Italy
State/province [94] 0 0
Torino
Country [95] 0 0
Japan
State/province [95] 0 0
Fukushima-Ken
Country [96] 0 0
Japan
State/province [96] 0 0
Osaka-Fu
Country [97] 0 0
Japan
State/province [97] 0 0
Tokyo-To
Country [98] 0 0
Japan
State/province [98] 0 0
Ehime
Country [99] 0 0
Japan
State/province [99] 0 0
Fukuoka
Country [100] 0 0
Japan
State/province [100] 0 0
Hiroshima
Country [101] 0 0
Japan
State/province [101] 0 0
Hokkaido
Country [102] 0 0
Japan
State/province [102] 0 0
Hyogo
Country [103] 0 0
Japan
State/province [103] 0 0
Kanagawa
Country [104] 0 0
Japan
State/province [104] 0 0
Kyoto
Country [105] 0 0
Japan
State/province [105] 0 0
Miyagi
Country [106] 0 0
Japan
State/province [106] 0 0
Nagoya
Country [107] 0 0
Japan
State/province [107] 0 0
Niigata
Country [108] 0 0
Japan
State/province [108] 0 0
Okayama
Country [109] 0 0
Japan
State/province [109] 0 0
Osaka
Country [110] 0 0
Japan
State/province [110] 0 0
Saitama
Country [111] 0 0
Japan
State/province [111] 0 0
Shizuoka
Country [112] 0 0
Japan
State/province [112] 0 0
Tokyo
Country [113] 0 0
Korea, Republic of
State/province [113] 0 0
Chungcheongbuk-do
Country [114] 0 0
Korea, Republic of
State/province [114] 0 0
Gyeonggi-do
Country [115] 0 0
Korea, Republic of
State/province [115] 0 0
Daegu
Country [116] 0 0
Korea, Republic of
State/province [116] 0 0
Goyang-si
Country [117] 0 0
Korea, Republic of
State/province [117] 0 0
Seoul
Country [118] 0 0
Spain
State/province [118] 0 0
Barcelona
Country [119] 0 0
Spain
State/province [119] 0 0
Cádiz
Country [120] 0 0
Spain
State/province [120] 0 0
La Coruña
Country [121] 0 0
Spain
State/province [121] 0 0
Tenerife
Country [122] 0 0
Spain
State/province [122] 0 0
Badajoz
Country [123] 0 0
Spain
State/province [123] 0 0
Lleida
Country [124] 0 0
Spain
State/province [124] 0 0
Madrid
Country [125] 0 0
Spain
State/province [125] 0 0
Málaga
Country [126] 0 0
Spain
State/province [126] 0 0
Salamanca
Country [127] 0 0
Spain
State/province [127] 0 0
Sevilla
Country [128] 0 0
Spain
State/province [128] 0 0
Valencia
Country [129] 0 0
Spain
State/province [129] 0 0
Zaragoza
Country [130] 0 0
Turkey
State/province [130] 0 0
Adana
Country [131] 0 0
Turkey
State/province [131] 0 0
Ankara
Country [132] 0 0
Turkey
State/province [132] 0 0
Antalya
Country [133] 0 0
Turkey
State/province [133] 0 0
Bursa
Country [134] 0 0
Turkey
State/province [134] 0 0
Istanbul
Country [135] 0 0
Turkey
State/province [135] 0 0
Izmir
Country [136] 0 0
Turkey
State/province [136] 0 0
Konya
Country [137] 0 0
Turkey
State/province [137] 0 0
Sakarya
Country [138] 0 0
Turkey
State/province [138] 0 0
Samsun
Country [139] 0 0
Turkey
State/province [139] 0 0
Tekirdag
Country [140] 0 0
United Kingdom
State/province [140] 0 0
Cornwall
Country [141] 0 0
United Kingdom
State/province [141] 0 0
Devon
Country [142] 0 0
United Kingdom
State/province [142] 0 0
Grampian Region
Country [143] 0 0
United Kingdom
State/province [143] 0 0
Greater London
Country [144] 0 0
United Kingdom
State/province [144] 0 0
Lothian Region
Country [145] 0 0
United Kingdom
State/province [145] 0 0
Nottinghamshire

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Daiichi Sankyo
Address
Country
Other collaborator category [1] 0 0
Commercial sector/industry
Name [1] 0 0
Daiichi Sankyo Co., Ltd.
Address [1] 0 0
Country [1] 0 0
Other collaborator category [2] 0 0
Commercial sector/industry
Name [2] 0 0
AstraZeneca
Address [2] 0 0
Country [2] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
This study will compare DS 8201a to standard treatment.

Participants must have HER2 breast cancer that has been treated before.

Their cancer:

* cannot be removed by an operation
* has spread to other parts of the body
Trial website
https://clinicaltrials.gov/study/NCT03523585
Trial related presentations / publications
Andre F, Hee Park Y, Kim SB, Takano T, Im SA, Borges G, Lima JP, Aksoy S, Gavila Gregori J, De Laurentiis M, Bianchini G, Roylance R, Miyoshi Y, Armstrong A, Sinha R, Ruiz Borrego M, Lim E, Ettl J, Yerushalmi R, Zagouri F, Duhoux FP, Fehm T, Gambhire D, Cathcart J, Wu C, Chu C, Egorov A, Krop I. Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023 May 27;401(10390):1773-1785. doi: 10.1016/S0140-6736(23)00725-0. Epub 2023 Apr 20. Erratum In: Lancet. 2023 Dec 9;402(10418):2196. doi: 10.1016/S0140-6736(23)02709-5. Lancet. 2024 Mar 9;403(10430):912. doi: 10.1016/S0140-6736(24)00420-3.
Fehm T, Cottone F, Dunton K, Andre F, Krop I, Park YH, De Laurentiis M, Miyoshi Y, Armstrong A, Borrego MR, Yerushalmi R, Duhoux FP, Takano T, Lu W, Egorov A, Kim SB. Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2024 May;25(5):614-625. doi: 10.1016/S1470-2045(24)00128-1.
Public notes

Contacts
Principal investigator
Name 0 0
Global Team Leader
Address 0 0
Daiichi Sankyo
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT03523585